The performance of synthetic hedge fund clones is strong enough to start to put pressure on the high fees charged by many real hedge funds, according to a comprehensive academic review of the controversial concept.

A swathe of hedge fund replication products have been launched by banks such as Goldman Sachs, JPMorgan, Barclays Capital and Bank of America Merrill Lynch since 2006.